TBL1 is required for the mesenchymal phenotype of transformed breast cancer cells by Rivero Canalejo, Sabrina et al.
Rivero et al. Cell Death and Disease           (2019) 10:95 
https://doi.org/10.1038/s41419-019-1310-1 Cell Death & Disease
ART ICLE Open Ac ce s s
TBL1 is required for the mesenchymal
phenotype of transformed breast
cancer cells
Sabrina Rivero1, Elena Gómez-Marín1, José A. Guerrero-Martínez1, Jorge García-Martínez1 and José C. Reyes 1
Abstract
The epithelial-to-mesenchymal transition (EMT) and its reversion (MET) are related to tumor cell dissemination and
migration, tumor circulating cell generation, cancer stem cells, chemoresistance, and metastasis formation. To identify
chromatin and epigenetic factors possibly involved in the process of EMT, we compare the levels of expression of
epigenetic genes in a transformed human breast epithelial cell line (HMEC-RAS) versus a stable clone of the same cell
line expressing the EMT master regulator ZEB1 (HMEC-RAS-ZEB1). One of the factors strongly induced in the HMEC-
RAS-ZEB1 cells was Transducin beta-like 1 (TBL1), a component of the NCoR complex, which has both corepressor and
coactivator activities. We show that TBL1 interacts with ZEB1 and that both factors cooperate to repress the promoter
of the epithelial gene E-cadherin (CDH1) and to autoactivate the ZEB1 promoter. Consistent with its central role, TBL1 is
required for mesenchymal phenotypes of transformed breast epithelial and breast cancer cell lines of the claudin-low
subtype. Importantly, a high expression of the TBL1 gene correlates with poor prognosis and increased proportion of
metastasis in breast cancer patients, indicating that the level of TBL1 expression can be used as a prognostic marker.
Introduction
Epithelial and mesenchymal cellular phenotypes are the
edges of a spectrum of states that can be transitory or
stable1. The process by which epithelial cells can down-
regulate epithelial characteristics and acquire a mesench-
ymal phenotype is called epithelial-to-mesenchymal
transition (EMT) and the reverse process, mesenchymal-
to-epithelial transition (MET). Both processes are not only
common during embryonic development2 but are also
involved in different stages of the metastatic cascade,
including tumor cell dissemination and migration3, gen-
eration of tumor circulating cells4, cancer stem cells5,6,
chemoresistance7,8, and metastasis formation9–12. During
EMT, cells undergo an extensive reorganization of cell
junction complexes, cytoskeletal architecture, and extra-
cellular matrix interactions1,2,13. Further, cells increase
their motility and invasion properties and become more
resistant to drugs. These transformations require large
changes in gene expression, which are controlled by
master transcription factors (EMT-TF), including SNAIL
(SNAI1 and SNAI2), TWIST, and zinc-ﬁnger E-box-
binding (ZEB) transcription factors (ZEB1 and ZEB2)13.
The SNAI1 and ZEB proteins are repressors of epithelial
genes and activators of mesenchymal genes. Multiple sig-
naling pathways, including transforming growth factor
(TGF)-β, WNT, Notch, and mitogen-activated protein
kinases, cooperate (in either an autocrine or paracrine
manner) to initiate EMT by increasing EMT-TF
expression13.
Both EMT and MET require extensive reorganization of
the epigenetic information of the cells14,15. For example,
SNAI1 represses transcription of epithelial genes, such as
CDH1 (which encodes E-cadherin), by recruiting
chromatin-modifying machineries, including the Polycomb
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repressive complex 2, the Lys-speciﬁc demethylase 1/REST
corepressor 1 complex, and H3K9 histone methyl-
transferases16–19. ZEB1 has been also shown to repress
CDH1 by recruiting the corepressor CtBP120 and the
chromatin remodeler BRG121. Thus identifying epigenetic
and chromatin regulators involved speciﬁcally in EMT and
MET is of paramount importance for better understanding
the mechanisms responsible for tumor cell dissemination
and metastasis formation, as well as for identifying putative
druggable targets. With this purpose, we analyzed pre-
viously published expression data of a RAS-transformed
human mammary epithelial cell line (HMEC-RAS) versus a
stable clone of the same cell line expressing ZEB1 and with
a strong mesenchymal phenotype (HMEC-RAS-ZEB1)22.
We rationalized that epigenetic genes strongly upregulated
in the ZEB1 expressing cells may be essential for the
mesenchymal phenotype. One of the most upregulated
genes was Transducin beta-like 1 (TBL1), encoding a
transcriptional cofactor that was described as a component
of the nuclear receptor corepressor (NCoR)/silencing
mediator for retinoid and thyroid receptors (SMRT)/his-
tone deacetylase 3 complex23. TBL1 overexpression has
been linked to pancreas cancer24 and oncogenic Wnt sig-
naling25, but its role in controlling the mesenchymal
phenotype has not been analyzed. We show that TBL1
interacts and cooperates with ZEB1 for repressing the
CDH1 promoter and for self-activation of the ZEB1 pro-
moter and that it is essential for the mesenchymal and
stem-like phenotypes. Downregulation of TBL1 in breast
cancer cell lines decreased cell invasion ability. In agree-
ment with this, human breast cancer tumors with high
expression of the TBL1 gene correlates with poor prog-
nosis and an increased proportion of metastasis.
Results
Differential expression of epigenetic genes in epithelial
versus mesenchymal mammary cells
To determine EMT-dependent changes of gene
expression of a set of 824 known and predicted chromatin
and epigenetic factors (Supplementary Table S1), we
analyzed previously published expression data of a H-
RASG12V-transformed human mammary epithelial cell
line (HMEC-RAS) versus a stable clone of the same cell
line expressing a recombinant mouse HA-tagged ZEB1
(HA-mZEB1) gene (HMEC-RAS-ZEB1)22. HMEC-RAS-
ZEB1 cells exhibit the transcriptional signature of
claudin-low tumors, including low expression of tight and
adherens junction genes, mesenchymal traits, and stem
cell-like characteristics22. Out of the 824 chromatin and
epigenetic genes, 112 were upregulated (Log2 fold-change
(FC) ≥ 1) and 32 were downregulated (Log2 FC ≤−1)
(Supplementary Table S1 and Fig. 1a). The two most
upregulated gene were LOX and PRDM1 (BLIMP-1), two
well-known factors involved in EMT26–28. The third most
upregulated gene was TBL1 (Fig. 1a). TBL1 together with
its paralogous partner TBLR1 regulate cofactor exchange
at nuclear receptor genes29. TBL1 and TBLR1 also control
β-catenin-mediated regulation of Wnt target genes25;
however, the role of TBL1 in regulation of epithelial genes
and EMT has not been previously investigated. TBL1
mRNA levels increased 46-fold in HMEC-RAS-ZEB1
versus HMEC-RAS by reverse transcription–quantitative
real-time polymerase chain reaction (RT-qPCR) (Fig. 1b),
conﬁrming the microarray data. Therefore, we selected
this protein for a deep characterization of its role in the
mesenchymal phenotypes. First, we determined TBL1
protein expression levels in HMEC-RAS-ZEB1 and
HMEC-RAS cells by western blotting and immuno-
ﬂuorescence. TBL1 protein levels were strongly increased
(30-fold increase) in the cell line overexpressing mZEB1
with respect to the control cell line (Fig. 1c, d). In con-
trast, the levels of TBLR1 were not signiﬁcantly changed.
Levels of ZEB1, CDH1 (epithelial marker), and VIM
(mesenchymal marker) were also determined as controls.
Figure 1b shows that, in addition to the HA-mZEB1
mRNA, HMEC-RAS-ZEB1 cells also presented increased
levels of the endogenous hZEB1 mRNA. Western blotting
and immunoﬂuorescence using an anti-ZEB1 that recog-
nizes both HA-ZEB1 and hZEB1 demonstrated increased
levels of ZEB1 protein in HMEC-RAS-ZEB1 respect
to HMEC-RAS cells, as expected (Fig. 1c, d). Levels of
CDH1 protein were much lower in HMEC-RAS-ZEB1
than in HMEC-RAS. Inversely, VIM levels increased
in HMEC-RAS-ZEB1 cells with respect to HMEC-RAS
cells. Interestingly, TBL1 was also upregulated 48 h
upon induction of EMT by TGF-β treatment in mouse
mammary epithelial cells NMuMG (Fig. 1e), suggesting
that TBL1 upregulation is a common feature of the
mesenchymal state.
TBL1 represses CDH1 expression
The E-cadherin encoding gene (CDH1) is a key epi-
thelial marker, and repression of this gene is a hallmark of
the EMT process13. Therefore, we tested whether TBL1 is
involved in controlling the expression of CDH1. Knock-
down of TBL1 in HMEC-RAS-ZEB1 cells by interference
RNA promoted upregulation of CDH1 at both the mRNA
and protein levels (Fig. 2). The CDH1 transcript was also
upregulated with a second independent small interfering
RNA (siRNA) that targeted TBL1 (Supplementary
Fig. S1A). Knockdown of ZEB1 by a siRNA that targets
both the endogenous hZEB1 (Fig. 2a and Supplementary
Fig. S1B) and the transgenic HA-mZEB1 (Supplementary
Fig. S1B) was also performed as control. Depletion of
ZEB1 also promoted the upregulation of CDH1, as
expected (Fig. 2a–e). Notably, knockdown of TBL1 or
ZEB1 increased the CDH1 transcript levels by 22.9- and
31.3-fold, respectively, while knockdown of both TBL1
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and ZEB1 at the same time increased transcript levels by
105.8-fold, indicating that both factors synergistically
cooperate to regulate CDH1 (Fig. 2a). Synergistic upre-
gulation was also observed at the level of protein levels
(6.8- and 7.0-fold, respectively, after independent knock-
down, versus 17.1-fold after combined knockdown)
(Fig. 2c, d). Depletion of TBL1 also decreased endogenous
hZEB1 expression at both the mRNA and protein levels,
suggesting that TBL1 directly or indirectly also controls
hZEB1 levels.
TBL1 cooperates with ZEB1 to regulate the CDH1 and
hZEB1 promoters
Next, we investigated whether TBL1 directly regulates
the CDH1 promoter. We used a reporter plasmid in which
expression of the luciferase gene is under the control of
the CDH1 promoter (region –178 to +92 with respect to
the transcriptional start site [TSS]). As expected, co-
transfection of an HA-ZEB1 expression plasmid with the
CDH1 promoter reporter construct reduced luciferase
activity levels (Fig. 3a). Interestingly, in the absence of
ZEB1, Flag-TBL1 did not repress the CDH1 promoter;
however, co-expression of Flag-TBL1 increased repres-
sion caused by HA-ZEB1, suggesting that TBL1 coop-
erates with ZEB1 to repress the CDH1 promoter (Fig. 3a).
We have also shown that knockdown of TBL1 decreases
the expression of endogenous hZEB1 (Fig. 2). Therefore,
we tested whether TBL1 regulates the ZEB1 promoter
(region −1079 to −80 with respect to the TSS), also
by using a luciferase reporter plasmid. In this case,
Fig. 1 Differential expression of epigenetic genes in epithelial versus mesenchymal mammary cells. a Scatter plot showing expression
proﬁles (Log2 scale) of 824 genes encoding epigenetic and chromatin factors (supplementary Table S1) from HMEC-RAS cells (x axis) and HMEC-RAS-
ZEB1 cells (y axis). Data obtained from GEO accession GSE3272722. Genes upregulated or downregulated more than two-fold (Log2 (fold change) ≥ 1
or Log2 (fold change) ≤ 1) are depicted in red or green, respectively. b TBL1, hZEB1, CDH1, and mZEB1 mRNA levels were determined by reverse
transcription–quantitative real-time polymerase chain reaction in HMEC-RAS and HMEC-RAS-ZEB1 cells. Data are the average of n= 6 data from three
independent experiments ± SD. *p < 0.05, **p < 0.01 versus control by ANOVA. c Whole-cell extracts from HMEC-RAS and HMEC-RAS-ZEB1 cells were
analyzed by western blot with the indicated antibodies. The anti-ZEB1 antibody recognizes both proteins, the endogenous hZEB1 and the transgenic
HA-mZEB1. Quantiﬁcation of different signals is shown. d Immunoﬂuorescence staining to detect the presence of the indicated proteins in HMEC-
RAS and HMEC-RAS-ZEB1 cells. Nuclei were stained with 4,6-diamidino-2-phenylindole. Bar, 10 μm. e Western blot analysis of TBL1, ZEB1, CDH1, and
α-tubulin with proteins extracted from NMuMG cells untreated and treated with 10 ng/ml TGF-β1 for 48 h. Quantiﬁcation of different signals is shown
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expression of Flag-TBL1 or HA-ZEB1 increased luciferase
activity (Fig. 3b). Co-expression of both factors together
further increased activity, again suggesting a cooperation
between both factors (Fig. 3b).
We then performed chromatin immunoprecipitation
(ChIP) experiments using HMEC-RAS-ZEB1 cells to
investigate whether endogenous TBL1 and ZEB1 are
directly recruited to the CDH1 and ZEB1 promoters. We
found that both TBL1 and ZEB1 were present at both
promoters (Fig. 3c). As a control, we veriﬁed that TBL1
depletion decreased TBL1 occupancy, conﬁrming the
speciﬁcity of the ChIP signals. Interestingly, TBL1
knockdown also decreased the occupancy of ZEB1 at both
the CDH1 and ZEB1 promoters (Fig. 3c), consistent with
the reduction of ZEB1 levels observed upon TBL1
depletion (Fig. 2).
We next tested whether TBL1 interacts physically with
ZEB1 by co-immunoprecipitation of transiently co-
expressed Flag-tagged TBL1 and HA-tagged ZEB1.
Indeed, HA-ZEB1 co-immunoprecipitated with Flag-TBL1
Fig. 2 TBL1 cooperates with ZEB1 to repress CDH1 gene expression. a Depletion of TBL1 and ZEB1 synergistically increases CDH1 gene
expression. TBL1, hZEB1, and CDH1 mRNA expression was analyzed by reverse transcription–quantitative real-time polymerase chain reaction in
HMEC-RAS-ZEB1 cells 72 h after transfection with the indicated small interfering RNAs (siRNAs). Data are the average of n= 6 data from three
independent experiments ± SD. *P < 0.05; **P < 0.01 versus control by analysis of variance (ANOVA). b–e Depletion of TBL1 increases CDH1 protein
expression. b Immunoﬂuorescence staining of CDH1 in HMEC-RAS-ZEB1 cells transfected with the indicated siRNAs. Nuclei were stained with
4,6-diamidino-2-phenylindole. Bar, 10 μm. c Quantiﬁcation of immunoﬂuorescence experiments shown in b. Total number of scored cells per
condition ≥200. d HMEC-RAS-ZEB1 cells were transfected with the indicated siRNAs. At 72 h after transfection, a total lysate was prepared and
analyzed by western blot for the indicated proteins. e Quantiﬁcation of TBL1, ZEB1, and CDH1 levels, normalized with respect to GAPDH expression.
Data are the average of three independent experiments ± SD. *P < 0.05; **P < 0.01 versus control by ANOVA
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(using anti-ﬂag antibodies) (Fig. 3d). Furthermore, endo-
genous ZEB1 also co-immunoprecipitated with endogen-
ous TBL1 protein in HMEC-RAS-ZEB1 cells (Fig. 3e).
As previously described, we found that TBL1 co-
immunoprecipitated with NCoR1 and TBLR1. However,
we did not ﬁnd that ZEB1 co-immunoprecipitated with
either NCoR1 or TBLR1. This fact may suggest that the
TBL1–ZEB1 interaction is partially independent of the
NCoR complex or that ZEB1 interacts with the complex
through TBL1. In summary, our data suggest that the
cooperation between ZEB1 and TBL1 for controlling the
CDH1 and ZEB1 promoters occurs through a physical
interaction.
TBL1 is essential for the mesenchymal phenotype of
HMEC-RAS-ZEB1 cells
Our results suggest that TBL1 is important for
repression of the CDH1 gene and for activation of ZEB1
gene, two important players of the mesenchymal phe-
notype. In agreement, HMEC-RAS-ZEB1 cells depleted
of TBL1 displayed a decreased mesenchymal-like
morphology that resemble the HMEC-RAS cellular
morphology (Supplementary Fig. S2a). Depletion of
TBL1 in HMEC-RAS-ZEB1 cells caused the expression
of CXADR and CLDN12 genes, two well-known
epithelial markers (Supplementary Fig. S2b). In addi-
tion, depletion of TBL1 provoked a small reduction of
cell proliferation (Supplementary Figure S3a) that could
not be correlated with changes in cell cycle (Supple-
mentary Figure S3b and S3c) and a small but signiﬁcant
increase of apoptosis from 2.5 to 5.5% of the cells
(Supplementary Figure S3d). Depletion of ZEB1 pro-
voked similar effects on cell proliferation and apoptosis.
Next, we checked whether TBL1 knockdown affects
cell motility and invasiveness of HMEC-RAS-ZEB1 cells,
two characteristics of mesenchymal cells. We also mon-
itored the effect of ZEB1 knockdown as a control. Scratch
assays demonstrated that TBL1 depletion decreased cell
motility to a similar extent as ZEB1 depletion (Fig. 4a, b).
Cell invasion was monitored by using Matrigel-coated
Boyden chambers. Both TBL1 and ZEB1 depletion
impaired invasiveness also to a similar extent in this assay
(Fig. 4c, d).
Upon EMT, certain cell types acquire stem cell-like
properties5,6. In fact, HMEC-RAS-ZEB1 cells are able to
form mammospheres22, a property associated with
Fig. 3 TBL1 and ZEB1 interact and cooperate for regulation of the CDH1 and ZEB1 promoters. a Reporter assay showing repression of the
CDH1 promoter by Flag-TBL1 and HA-ZEB1 in NMuMG cells. b Reporter assay showing activation of the ZEB1 promoter by Flag-TBL1 and HA-ZEB1 in
HEK293T cells. c TBL1 and ZEB1 bind to the CDH1 and ZEB1 promoters. HMEC-RAS-ZEB1 cells transfected with control siRNAs (siControl) or siRNAs
against TBL1 (siTBL1) were subjected to chromatin immunoprecipitation assays with the indicated antibodies. Fold enrichment indicate occupancies
relative to siControl. a–c Values are the average of n= 6 data from three independent experiments ± SD. *P < 0.05; **P < 0.01, as compared to control
or between the indicated samples, determined by analysis of variance. d, e TBL1 interacts with ZEB1 and CDH1. d HEK293T cells were transfected
with expression vectors encoding Flag-TBL1 and HA-ZEB1. Cell extracts were subjected to immunoprecipitation with anti-Flag or control (IgG)
antibodies and analyzed by Western blot for the presence of the indicated proteins. e Whole cell extracts from HMEC-RAS-ZEB1 cells were subjected
to immunoprecipitation with anti-ZEB1, anti-TBL1, anti-TBLR1, anti-NCoR, or control (IgG) antibodies. Immunoprecipitated proteins and 3% of the
input were analyzed by western blot with the indicated antibodies
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mammary epithelial stem cells30. Interestingly, TBL1
depletion decreased the ability of HMEC-RAS-ZEB1 cells
to form mammospheres (Fig. 4e, f). As expected, ZEB1
depletion also inhibited the mammosphere-formation
ability. Taken together, these data indicate that high
levels of TBL1 are required for the maintenance of
mesenchymal and at least one of the stem cell-like
properties of HMEC-RAS-ZEB1 cells.
TBL1 in breast cancer
HMEC-RAS-ZEB1 cells exhibit characteristics of
claudin-low breast tumor cells22. We thus investigated the
role of TBL1 in two breast cancer cell lines with claudin-
low characteristics: MDA-MB-231 and BT-54931. In
agreement with the data obtained with HMEC-RAS-ZEB1,
downregulation of TBL1 in both cell lines signiﬁcantly
increased the levels of CDH1 protein (Fig. 5a, b). Fur-
thermore, depletion of TBL1 also decreased cell invasive-
ness of both cell lines. Similar results have been reported
in the cell line MDA-MB-231 using a lentiviral-based
silencing strategy32. These data conﬁrm that TBL1 is
required for the mesenchymal traits of cell lines with
claudin-low characteristics (Fig. 5c, d).
These results made us to explore whether TBL1 might
have a role in breast cancer. For that, RNA-seq and
clinicopathological data of the breast invasive carcinoma
Fig. 4 TBL1 is required for migration, invasion, and mammosphere-formation phenotypes of HMEC-RAS-ZEB1 cells. a, b TBL1 depletion
inhibits cell migration in scratch assays. a HMEC-RAS-ZEB1 cells were transfected with the indicated siRNAs. Cells were plated 72 h after transfection
onto culture inserts, which were removed 24 h later. Phase-contrast pictures of the wounds at different locations were taken at the time of removal
and again 24 h later. b Quantiﬁcation of the representative scratch assays shown in a. Cells in the wound area were counted over four microscopic
ﬁelds for each condition. c, d TBL1 is required for HMEC-RAS-ZEB1 invasiveness. HMEC-RAS-ZEB1 cells were transfected with the indicated siRNAs. At
72 h after transfection, identical number of cells of each treatment were deposited on Matrigel-coated ﬁlters and allowed to invade during 18 h. The
migrating cells were then stained and visualized by microscopy. Duplicate ﬁlters were counted in three individual experiments (d). e Mammosphere-
formation assay under low adherence conditions. f Quantiﬁcation of mammosphere-formation assay. b, d, f Values are average of three independent
experiments ± SD. *P < 0.05, **P < 0.01 as compared to control and determined by analysis of variance
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cohort from The Cancer Genome Atlas (TCGA) were
analyzed. Levels of TBL1 transcript expression were not
signiﬁcantly higher in normal tissue than in cancer tissue
samples. We next divided the tumor samples into two
groups according to the TBL1 gene expression and
compared survival plots of patients with TBL1-low
tumors with those of patients with TBL1-high tumors.
Strikingly, patients with TBL1-high tumors presented a
median survival of 113.7 months, while patients with
TBL1-low tumors presented a median survival of
212.1 months (log-rank test P value= 0.0023), indicating
that a high expression of TBL1 transcript is associated
with poor prognosis (Fig. 5e). No differences in prognosis
were associated with high versus low levels of TBLR1
transcript (Fig. 5f). We then investigated whether
expression levels of the TBL1 gene was associated with
speciﬁc clinicopathological factors such as sex, age, tumor
stage (T1 to T4 and stage I to IV), lymph node metastasis
(N), or distant metastasis (M) (Table 1). Interestingly, we
observed a signiﬁcantly higher proportion of stage IV
tumors in the group of patients with TBL1-high tumors
(P= 0.033). Likewise, distant metastasis (M1) was also
more abundant in the TBL1-high than in the TBL1-low
patient group (P= 0.041). No signiﬁcant differences in
clinicopathological factors were associated with high
versus low levels of TBLR1.
Discussion
In this manuscript, we analyze a number of chromatin
and epigenetic factors that are upregulated in a
mesenchymal transformed cell lines with respect to its
parental epithelial counterpart. Among the upregulated
factors, we found components of the SWI/SNF complex
(SMARCA4, SMARCA2, ARID1A) and the Polycomb
complex (EED, SUZ12 and BMI), two complexes well
known to be involved in the EMT process18,21. Other
upregulated factors, such as LOX and PRDM1, have been
previously associated to EMT26–28. One of the factors
that changed drastically its expression levels was TBL1, a
well-known coregulator of nuclear receptors and
β-catenin23,25, whose involvement in EMT is not char-
acterized. We have investigated the involvement of TBL1
in CDH1 repression and maintenance of the mesenchy-
mal state. We show that TBL1 regulates the mesenchymal
phenotype both by acting as a corepressor of the CDH1
gene with ZEB1 and by acting positively on ZEB1 auto-
activation. In addition, ChIP experiments demonstrated
that TBL1 binds to both CDH1 and ZEB1 endogenous
Fig. 5 TBL1 is required for mesenchymal traits in breast cancer cells. a, b Depletion of TBL1 increases levels of CDH1 protein in BT-549 (a) and
MDA-MB-231 cells (b). Cells were transfected with the indicated small interfering RNAs (siRNAs). At 72 h after transfection, CDH1, TBL1, and GAPDH
expression was analyzed by western blot. c, d TBL1 depletion inhibits cell invasion in BT-549 (c) and MDA-MB-231 cells (d). Cells were transfected with
the indicated siRNAs, and cell motility through Matrigel-coated ﬁlters was measured at 18 h after plating. The migrating cells were then stained and
visualized by microscopy. Duplicate ﬁlters were counted in three individual experiments. Depletion of ZEB1 was performed as a control. Values are
the average of three independent experiments ± SD. *P < 0.05 as compared to control and determined by analysis of variance. e, f Kaplan–Meier
survival plots for breast carcinoma patients from The Cancer Genome Atlas. Patients were divided into subgroups according to the TBL1 (e) or TBLR1
(f) mRNA expression (RNA-seq data). P values were calculated by log-rank test
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promoters. Interestingly, depletion of TBL1 strongly
decreased ZEB1 occupancy at the CDH1 and ZEB1 pro-
moters, which is consistent with the reduction of ZEB1
levels we observed after TBL1 knockdown. It is also
possible that TBL1 has a role in stabilizing ZEB1 at the
chromatin of both gene promoters.
How does TBL1 behave at the same time as a coacti-
vator and a corepressor? It has been shown that ZEB1 can
act as a repressor by interacting with and recruiting the
chromatin factors CtBP and BRG1, but it also can act as
an activator through its interaction with the acetyl-
transferase P30020,21,33,34. Interestingly, our data suggest
that, in contrast to the previously identiﬁed chromatin
coregulators, TBL1 cooperates with ZEB1 for both its
activation and repression functions. It is unclear how
ZEB1 turns from a repressor to an activator; however,
recent studies suggest that its conversion to an activator
requires the action of the Wnt/β-catenin pathway35. TBL1
was initially described as a subunit of the repressor
complex NCoR23. It soon became clear, however, that
TBL1 and TBLR1 mediate exchange of the nuclear
receptor corepressors NCoR and SMRT for coactivators
upon ligand binding29; they were thus termed exchange
factors. TBL1 recruits β-catenin to Wnt target genes for
activation36, and ZEB1 is activated by the Wnt/β-catenin
pathway37. We now show here that TBL1 interacts
directly with ZEB1. Therefore, it is possible that TBL1
mediates ZEB1-dependent repression of CDH1 through
the NCoR complex and that it also mediates activation of
ZEB1 gene expression through its ability to interacts with
β-catenin. This exempliﬁes a novel exchange activity of
TBL1 that, in this case, is important for the stabilization
of the mesenchymal phenotype of HMEC-RAS-ZEB1
cells. Consequently, TBL1 depletion impairs motility,
invasiveness, and mammosphere-formation phenotypes of
HMEC-RAS-ZEB1 cells.
Interestingly, TBL1 depletion also reduces mesenchy-
mal traits of breast cancer cell lines of the claudin-low
subtype. Claudin-low breast tumors are associated with
early metastasis and resistance to chemotherapy, and its
transcriptome is characterized by the expression of mar-
kers of EMT31,38–40. Consistent with an important role of
Table 1 Association between TBL1 and TBLR1 mRNA expression and clinicopathological factors in the breast carcinoma
dataset from TCGA










Age 58.67 ± 14.1 58.19 ± 12.7 0.53a 57.50 ± 12.9 58.8 ± 13.4 0.11a
Sex 1b 0.67b
Male 389 (98.9%) 697 (98.9%) 389 (98.7%) 698 (99.0%)
Female 4 (1.0%) 8 (1.1%) 5 (1.3%) 7 (1.0%)
Tumor stage (T) 0.305b 0.061b
T1+T2 319 (82.2%) 600 (84.6%) 341 (86.6%) 578 (82.2%)
T3+T4 69 (17.8%) 109 (15.4%) 53 (13.5%) 125 (17.8%)
Tumor stage (S) 0.033b 0.13b
SI+SII+SIII 367 (96.9%) 689 (98.7%) 384 (99.0%) 676 (97.7%)




N0 172 (45.0%) 344 (49.0%) 200 (51.4%) 315 (45.7%)




M0 325 (96.4%) 590 (98.5 %) 354 (98.6%) 561 (97.1%)
M1 12 (3.6%) 9 (1.5%) 5 (1.4%) 17 (2.9%)
aStudent's t test
bChi-square test. Signiﬁcant P values (P ≤ 0.05) are depicted in bold
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TBL1 in regulating EMT, and with a role of EMT in
tumor dissemination in at least certain types of breast
cancer, we observed that patients who had tumors with
high levels of TBL1 also presented a higher proportion
of metastasis. This fact is in agreement with a poor
prognosis of patients presenting breast tumors with high
levels of TBL1. High levels of TBL1 have also been
recently associated with poor prognosis in pancreatic
ductal adenocarcinoma24, suggesting that TBL1 is an
important prognosis marker in several cancer types.
In summary, our data contribute to emphasizing the
critical involvement of different chromatin regulatory
factors in the transcriptional reorganization that occurs
during EMT. We have characterized here the important
role of TBL1 in maintaining the mesenchymal phenotype
in cell lines with claudin-low characteristics. How the
different factors are coordinated among themselves, and
why a high number of chromatin regulatory machineries
are required to control one single gene such as CDH1, are
interesting questions to be addressed in future.
Materials and methods
Cells and treatments
Human mammary epithelial cells HMEC-RAS and
HMEC-RAS-ZEB1, kindly provided by Alain Puisieux
(Lyon, France) in 2014, were grown in Dulbecco’s mod-
iﬁed Eagle’s medium (DMEM)/F12 complemented with
10% fetal bovine serum (FBS), 10 ng/mL epidermal
growth factor (EGF), 0.5 µg/mL hydrocortisone, and 10
µg/mL insulin. The human breast cancer cell line MDA-
MB-231 (provided by Abelardo Lopez-Rivas, CABIMER,
in 2014) and human embryonic kidney cell line 293T
(provided by Rosa Ríos, CABIMER, in 2010) were grown
in DMEM supplemented with 10% FBS. Normal murine
mammary gland NMuMG cells (provided by José Antonio
Pintor-Toro, CABIMER, in 2014) were cultured in
DMEM medium supplemented with 10% FBS and 10 µg/
mL insulin. BT-549 cells (provided by Abelardo Lopez-
Rivas, CABIMER, in 2017) were cultured in DMEM/F12
medium supplemented with 10% FBS and 10 µg/mL
insulin. All cell lines were tested for mycoplasma infection
once per year using the MycoAlert Detection Kit (Lonza).
Before freezing, the stocks cells were treated with the anti-
mycoplasma antibiotics Plasmocin (InvivoGen). All cell
lines were propagated no more than 15 passages after
defrosting the stocks and not further authenticated.
Transient EMT was induced by the addition of TGF-β1
(10 ng/mL; R&D Systems) for 48 h.
Microarray data and selection of chromatin and epigenetic
factors
Relative mRNA levels of 824 genes encoding epigenetic
and chromatin factors of HMEC-RAS-ZEB1 and HMEC-
RAS cell lines were obtained from GEO accession
GSE3272722 (Supplementary Table S1). The selection of
824 chromatin and epigenetic factors was carried out by
combining epigenetic factors of the EpiFactors database41
and a previously published list of factors42 containing the
following protein domains or functions: PHD, BROMO,
CHROMO, PWWP, tandem BRCT, TUDOR, BAH, MBT,
SET, JMJC, JMJN, PRMT, HAT, HDAC, SIRT, DNMT,
MBD, and SNF2 ATP-dependent remodelers.
DNA constructs
The full-length human Flag-TBL1 expression plasmid
was kindly provided by Cun-Yu Wang25; the full-length
human HA-ZEB1 expression plasmid by Thomas Bra-
bletz43; the CDH1 gene promoter reporter plasmid pGL3-
E-cad (−178 to +92) by A. García de Herreros44; and the
ZEB1 gene promoter (–1079 to –80) reporter plasmid
pGL4.15-ZEB1 by Min Yu45.
Transfections and luciferase reporter assays
Transient transfections of cells with expression or
reporter plasmids were performed with Lipofectamine
(Invitrogen) or FuGENE HD (Promega) for 293T cells.
For siRNA transfections, we use Oligofectamine (Invi-
trogen), for HMEC-ZEB1 cells, and RNAiMAX (Invitro-
gen), for NMuMG cells. The siRNA sequences are shown
in Supplementary Table S2. siRNA against ZEB1 was
designed to target both the hZEB1 and the HA-mZEB1
mRNAs.
Luciferase assay were performed as previously descri-
bed19. The total amount of DNA in each individual well
was kept constant by adding empty vector (Flag or HA) as
appropriated.
Antibodies, western blotting, immunoprecipitation, and
immunohistochemistry
Co-immunoprecipitation, immunohistochemistry, and
western blotting were performed as previously descri-
bed46. The antibodies used for immunoprecipitation and
western blot were: mouse monoclonal anti-Flag (M2,
F1804, Sigma-Aldrich), rabbit polyclonal anti-ZEB1 (H-
102, Santa Cruz), mouse monoclonal anti-TBL1 (F-2,
Santa Cruz), rabbit polyclonal anti-TBLR1 (Bethyl),
mouse monoclonal anti-VIM (v5255, Sigma), mouse
monoclonal anti-E-cadherin (BD Transduction Labora-
tories, BD Biosciences, San Jose, CA, USA), mouse
monoclonal anti-GAPDH (6C5, Santa Cruz), and mouse
monoclonal anti-α-tubulin (T9026, Sigma-Aldrich). The
secondary antibodies used were IRDye 680 goat anti-
mouse IgG (H+L) antibody (926-68070, LiCOR) and
IRDye 800 goat anti-rabbit IgG (H+L) antibody (926-
32211, LiCOR). Antibodies used in ChIP experiments
were the rabbit polyclonal anti-ZEB1 (H-102, Santa Cruz)
and the mouse monoclonal anti-TBL1 (Ab24548, Abcam).
Antibodies used in immunoﬂuorescence were the mouse
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monoclonal anti-TBL1 (F-2, Santa Cruz), rabbit poly-
clonal anti-ZEB1 (H-102, Santa Cruz), and the mouse
monoclonal anti-E-cadherin (67A4, Santa Cruz). Sec-
ondary antibodies used were Texas Red dye-conjugated
goat anti-mouse IgG (Jackson ImmunoResearch) and
ﬂuorescein isothiocyanate-conjugated goat anti-mouse
IgG (Molecular Probes). For quantiﬁcation of immuno-
ﬂuorescences shown in Fig. 2b, 11 different microscopic
ﬁelds per condition were counted and the percentage of
CDH1-expressing cells with respect to the total number
of cells were represented. Total number of scored cells per
condition ≥200.
Growth curves, cell cycle, and apoptosis analysis
For cell growth analysis, 105 cells were seeded in
6-well plates. Every 24 h, cells of a well were collected
and counted using a Neubauer hemocytometer up to
t= 5 days. At t= 0, 3, and 5 days, silencing was mon-
itored by RT-qPCR. Cell cycle and apoptosis were
determined by ﬂow cytometry. For that, cells were
harvested, washed with phosphate-buffered saline (PBS)
and resuspended in ice-cold PBS. Ethanol (70%) was
added dropwise while vortexing at low speed, and cells
were then ﬁxed at 4 °C for at least 1 h. Cells were washed
with PBS and treated with ﬂuorescence-activated cell
sorting (FACS) buffer (250 μg/mL RNase A [Sigma-
Aldrich], and 10 μg/mL propidium iodide diluted in
PBS). Cells were incubated at 37 °C for 30 min and then
analyzed using a FACSCalibur (BD). Apoptosis was
determined by measuring the percentage of cells con-
taining a subG1 DNA content.
Scratch assays and invasion assays
Scratch assays were performed as previously descri-
bed19. At 24 h after transfection with either control, ZEB1,
or TBL1 siRNAs, an equal number of cells were plated
into culture inserts (Ibidi, Martinsried, Germany) and
incubated at 37 °C for 24 h. The next day, the culture
inserts were removed, and the wound was imaged at 0 and
24 h. To monitor cell invasion, Boyden chambers assays
were used as previously described47, with 24-well Trans-
well 8-µm ﬁlters that were coated with 10 µg growth
factor-reduced Matrigel (Trevigen). Complete medium
was used as a chemoattractant. At 72 h after transfection
with either siControl, siZEB1, or siTBL1, cells were
trypsinized and counted. Then cell suspension containing
105 cells in 0.5 ml Dulbecco's Modiﬁed Eagle's Med-
ium and 0.1% bovine serum albumin were placed into the
upper compartment of the Boyden chamber. Cell were
allowed to invade for 18 h. Then cells on the ﬁlter top
surface were removed and cells that had penetrated the
ﬁlters were nuclear-stained with 4,6-diamidino-2-pheny-
lindole. After the nuclei were counted, invaded cells were
expressed as the average number of migrated cells bound
per microscopic ﬁeld over seven ﬁelds per assay in tri-
plicate experiments.
Mammosphere formation
For mammosphere formation, single cells were plated
on a 60-mm ultra-low attachment tissue culture dish
(Corning, Lowell, MA, USA) at a density of 105 cells/mL
in DMEM/F12 complemented with 10% FBS, 10 ng/mL
EGF, 0.5 hydrocortisone, and 10 µg/mL insulin and
incubated for 8 days.
RNA extraction and RT-qPCR
Total RNA was prepared by using the RNeasy Kit
(Qiagen), as described in the manufacturer’s instruc-
tions, including DNase I digestion to avoid potential
DNA contamination. cDNA was generated from 100 ng
of total RNA by using SuperScript First Strand Synthesis
System (Invitrogen). Two µg of generated cDNA
solution was used as a template for real-time PCR
(qPCR). Gene products were quantiﬁed by qPCR
with the Applied Biosystems 7500 FAST Real-Time
PCR System, using Applied Biosystems Power SYBR
Green Master Mix. Values were normalized to the
expression of the GAPDH housekeeping gene. Each
experiment was performed at least in triplicate. All
oligonucleotide sequences used are listed in Supple-
mentary Table S3.
ChIP assays
ChIP assays were performed as previously described48.
Quantiﬁcation of immunoprecipitated DNA was per-
formed by qPCR. ChIP was quantiﬁed by using three
qPCR determinations. Provided data are the average of
at least three independent experiments. All oligonu-
cleotide sequences used are listed in Supplementary
Table S3.
Analysis of TCGA data
RNA-seq expression data and clinical data of the breast
carcinoma cohort were obtained from The Cancer Gen-
ome Atlas (http://cancergenome.nih.gov/)49. Survival
plots and the log-rank test were performed using
GraphPad Prism version 5.0. For tumor description, the
Tumor–Node–Metastasis (TNM) staging system (www.
cancerstaging.org/) was used, whereby T followed by a
number (1–4) describes the size of the tumor (with T4
being the largest); N followed by 1 or 0 indicates whether
lymph nodes have metastasis or not, respectively; and M
followed by 1 or 0 indicates whether the tumor has
metastasized or not, respectively. We also considered the
roman numeral stage annotation (S) from I to IV, with
each number corresponding approximately to a combi-
nation of the TNM numbers. No subdivisions of stages
were used. Signiﬁcance of differences between groups
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were computed using Prism 5 (GraphPad) and either
Student’s t test or Chi-square test, with conﬁdence
interval of 95%.
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